Patents by Inventor Gideon Pilarski

Gideon Pilarski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes for preparing cilostazol
    Patent number: 6515128
    Abstract: The present invention provides processes for preparing cilostazol and processes for purifying cilostazol by recrystallization.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: February 4, 2003
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Processes for preparing cilostazol
    Publication number: 20020099213
    Abstract: The present invention provides processes for preparing cilostazol and processes for purifying cilostazol by recrystallization.
    Type: Application
    Filed: August 14, 2001
    Publication date: July 25, 2002
    Inventors: Marioara Mendelovici, Nina Finkelstein, Gideon Pilarski
  • Stable gabapentin having pH within a controlled range
    Publication number: 20020045662
    Abstract: A pharmaceutical composition containing substantially pure and stable gabapentin are disclosed wherein gabapentin has a pH of between 6.8 to 7.3.
    Type: Application
    Filed: June 15, 2001
    Publication date: April 18, 2002
    Inventors: Claude Singer, Gideon Pilarski, Michael Pesachovich
  • Preparation of gabapentin
    Patent number: 6255526
    Abstract: There is disclosed a method of converting gabapenting hydrochloride substantially free of inorganic salts to gabapenting form II. The method comprises the steps of: (1) obtaining gabapentin hydrochloride that is substantially free of inorganic salts; (2) mixing a solution of the gabapenting hydrochloride with an additional amine in a first solvent so as to obtain a precipitate comprising gabapenting; and then (3) recovering gabapentin form II from the precipitate. The precipitated gabapentin is a novel polymorphic form of gabapentin possessing a crystalline structure characterized by novel sets of peaks in the powder X-ray diffraction pattern and in the FTIR spectra. This newly disclosed polymorph of gabapentin is characterized herein as gabapentin form III.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: July 3, 2001
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Michael Pesachovich, Claude Singer, Gideon Pilarski